The Primary Ciliary Dyskinesia Market is anticipated to Witness Significant Growth due to Rising Disease Prevalence
The Primary Ciliary Dyskinesia Market is anticipated to Witness Significant Growth due to Rising Disease Prevalence
Blog Article
Primary ciliary dyskinesia (PCD), also known as immotile cilia syndrome or Kartagener syndrome, is a rare genetic condition that affects the function of cilia throughout the body. Cilia normally help with fluid drainage in the airways and mucus clearance from the lungs. In PCD, the cilia do not beat or move properly, which leads to fluid buildup and recurrent respiratory infections such as pneumonia, bronchiectasis, and chronic sinusitis.
Symptoms often appear in childhood and include frequent respiratory infections, sinusitis, and ear infections. Diagnosis typically requires specialized tests to examine cilia function and structure under a microscope. There is no cure for PCD, but treatments aim to manage symptoms and prevent further damage
The primary ciliary dyskinesia market is estimated to be valued at USD 538.2 Mn in 2024 and is expected to reach USD 784.5 Mn by 2031, growing at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2031.
Key Takeaways
Key players operating in the primary ciliary dyskinesia market include AstraZeneca, Novartis, GSK, and Teva Pharmaceutical. These players are involved in research and development activities for developing advanced drugs and diagnostics for PCD.
The growing awareness about symptoms and available diagnostic tests represents a key opportunity in the Primary Ciliary Dyskinesia Market. Various non-profit organizations are educating patients and healthcare providers to aid early diagnosis.
Geographically, North America dominated the global market in 2019 due to the strong diagnostic infrastructure and high healthcare expenditure. However, the market is expanding in Asia Pacific and Europe due to increasing research activities.
Market Drivers
The rising prevalence of respiratory illnesses globally due to increasing risk factors such as pollution and smoking is driving the need for effective PCD treatments. As per recent estimates, at least 1 in 15,000-30,000 children are affected by PCD worldwide.
Market Restraints
However, the market growth can be hindered due to the rare disease classification of PCD limiting the target patient pool. Additionally, high costs of specialized diagnostic tests and lack of disease awareness in developing nations also hamper the overall market revenues.
Segment Analysis
The primary ciliary dyskinesia market is segmented into diagnosis and treatment. The diagnosis segment dominates the market as there is no permanent cure available and diagnosis plays a major role in the management of the disease. Diagnosis includes tests like nasal nitric oxide test, genetic testing, electron microscopy which help determine if a person has primary ciliary dyskinesia. The treatment segment is further divided into medication and airway clearance techniques. Antibiotics are prescribed to treat respiratory infections prevalent in this condition. Airway clearance techniques like postural drainage help keep lungs clear of mucus.
Global Analysis
North America holds the largest share in the primary ciliary dyskinesia market owing to increasing awareness, developed healthcare infrastructure and availability of advanced diagnostic techniques. Europe is the second largest market due to growing research activity and support from government and allied bodies for rare diseases. The Asia Pacific region is expected to witness the highest growth rate during the forecast period due to rising healthcare expenditure, growing focus on respiratory disorders and increasing patient pool.
Get more insights on: Primary Ciliary Dyskinesia Market
Author Bio:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)